艾媒报告|2019-2021年中国中药材用户调研及延伸市场研究报告

本报告研究涉及企业/品牌/案例：同仁堂，片仔癀，东阿阿胶，太极集团，胡庆余堂，同仁牛黄清心丸，黄芪颗粒，雷氏丹参片，云峰气血口服液，太极五子衍宗丸，太极生力雄丸，仲景左归丸，一笑堂龟甲壳，白云山复方丹参片，天士力养血清脑颗粒，白云山夏桑菊颗粒，白云山板蓝根颗粒

随着居民消费水平的提升和健康保健意识的增强，总体健康需求在扩大，进而推动中医药市场的发展，2018年中国中药材市场规模达1246亿元，同比增长22.40%，预计到2024年，中药材市场规模将达2004亿元。
iiMedia Research（艾媒咨询）调查显示，2019年接近五成受访者购买过中药材，滋补养生和治病是购买中药材的两大目的。由于中医药应用范围广泛，中医药产业链不断扩展延伸，并加速扩展和整合。同仁堂、片仔癀、东阿阿胶等中药巨头企业纷纷布局中药材后市场，建设中药大健康产业，如植物提取物、保健食品、中药化妆品等，已成为我国生命健康产业中最具成长性的组成部分。
According to the iiMedia Research survey, nearly 50% of respondents have bought Chinese herbal medicines in 2019, and tonic sage and cure are the two main purposes for buying Chinese herbal medicines. Due to the wide range of applications of Chinese medicine, the Chinese medicine industry chain continues to expand and expand and accelerate the expansion and integration. Tongrentang, tablets, Dong'a gum and other Chinese medicine giant enterprises have laid out the chinese medicine after the market, the construction of chinese medicine large health industry, such as plant extracts, health food, Chinese medicine cosmetics, etc., has become China's life and health industry in the most growth component.

（以下为节选页，完整版共88页）

艾媒报告|2019-2021年中国中药材行业发展现状及产业链分析报告

本报告研究涉及企业/品牌/案例：白云山,同仁堂,云南白药,昆明制药,华润三九,天士力,央视财经,牛黄,薏仁,茯苓,黄芪,川芎,片仔癀,中国中药,紫鑫药业,九洲药业,陇神戎发,众生药业,通化金马,江中药业,寿仙谷,新天药业,盘龙药业,佛慈制药,昆药集团,香雪制药,六味地黄丸,人参养荣丸,四神丸,白蚀丸,血脂康胶囊,茵栀黄口服液,一捻金胶囊,乙肝益气解郁颗粒,二十七味定坤丸,十六味冬青丸,参芪消渴胶囊,十香返生丸,华润三九,红日药业,源和药业,太龙药业,中智药业，培力控股,盛实百草,芍花堂,亳药千草,汇群中药

国内经济增长以及居民消费水平的提高都刺激着中药医疗消费需求的增长。iiMedia Research（艾媒咨询）调查显示，有49%的受访用户倾向中医药治疗，与西药基本持平。2018年中国中药材市场规模达1246亿元，同比增长22.40%，在巨大的需求驱动下，中药材种植面积扩大，药材产量将会持续增长。

中药材主要包括上游种植、养殖市场，中游流通市场和下游销售市场三大环节。目前，中药饮片和中成药生产是中药产业的核心，主要包括中药加工，包括中药配方颗粒、中药饮片加工、中成药制造等。中药饮片领域方面，行业销售收入增速分别在2016和2018年触底回升，华润三九、中国中药、红日药业等上市公司表现良好；中药配方颗粒方面，2006-2016年，中国市场销售额占饮片市场销售额比重由1.2%增加至6.0%，中药配方颗粒或将成为中药饮片加工行业应用广泛的产品；中成药方面，随着国家医改政策的推行，中成药消费需求趋于合理，中成药产量开始回落，但仍处于一个比较高的产量水平，云南白药、白云山、同仁堂、紫鑫药业等上市企业表现良好。

Chinese medicinal materials mainly include upstream planting, breeding market, midstream circulation market and downstream sales market three links. At present, the production of Chinese medicine tablets and traditional Chinese medicine is the core of the Chinese medicine industry, including the processing of Traditional Chinese medicine, including Chinese medicine formula particles, Chinese medicine tablet processing, traditional Chinese medicine manufacturing. In the field of Chinese medicine tablets, the growth rate of sales revenue in the industry rebounded in 2016 and 2018, respectively, china Resources 39, Chinese medicine, Red Day Pharmaceuticals and other listed companies performed well; Chinese medicine formula particles may become a widely used product in the Chinese medicine tablet processing industry, Chinese medicine, with the implementation of the national medical reform policy, the consumption demand of traditional Chinese medicine tends to be reasonable, the production of Traditional Chinese medicine began to fall, but still at a relatively high level of production, Yunnan White Medicine, Baiyunshan, Tongrentang, Zixin Pharmaceutical and other listed enterprises performed well.

艾媒咨询|2020年第三季度中国中药材行业数据监测季度报告

本报告研究涉及企业/品牌/案例：同仁堂、香雪制药、白云山。

数据显示，2020年第三季度，中药材价格指数迎来上涨周期。艾媒咨询分析师认为，受动物类等少数品种拉动影响，预计2020年10-11月中药材指数会持续走高，但是在12月维稳。据调查，绝大多数商户将会在2021年密切关注行业相关政策、谨慎经营，采取减少压货炒作等经营方式。因而，预计中药材市场在2020年末旺季会有一波行情的走高，但随着旺季结束，明年年初的价格会重新回落，随着疫情的常态化，中药材市场行情预期会呈周期性波动的态势。

Data show that in the third quarter of 2020, Chinese Herbal Medicine Price Index ushered in an upward cycle. iiMedia Research believe that by a small number of animals and other species pull the impact of October 2020-november Chinese herbal medicine index is expected to continue to rise, but stable in December. According to the survey, the vast majority of businesses in the 2021 will pay close attention to industry-related policies, prudent management, to reduce speculation and other business practices. As a result, the Chinese herbal medicine market is expected to see a wave of rising prices in the peak season at the end of 2020. However, as the peak season ends, prices will fall back early next year, and as the epidemic becomes more normal, chinese medicinal materials market is expected to be cyclical fluctuations in the situation.

艾媒咨询|2020Q2中国中药材行业季度数据监测报告

本报告研究涉及企业/品牌/案例：云南白药，天士力。

数据显示，2020年4-5月中药材价格指数小幅下降，行情总体较为震荡。艾媒咨询分析师认为，自第二季度起中药材基本不受新冠肺炎疫情影响，市场秩序趋于稳定，但需求仍然不足，中药材基本以减产居多，减产的信号给予商家部分信心，一旦消费情况好转，中药材价格会重新上涨，因此商家谨慎投资与积极备货双管齐下，导致第二季度中药材大盘指数震荡。

Data show that the price index of Chinese medicinal materials declined slightly from April to May 2020, and the market was generally volatile. iiMedia Research believe that since the second quarter, Chinese herbal medicines have basically not been affected by the new coronary pneumonia epidemic. The market order has stabilized, but demand is still insufficient. Basically, Chinese herbal medicines basically reduce production. The signal of reduced production gives businesses some confidence. Once consumed The situation improves, and the prices of Chinese herbal medicines will rise again. Therefore, merchants' cautious investment and active inventory preparation have taken two measures, leading to the second quarter Chinese herbal medicines market index shock.

中国医药2021年第三季度报告

中新药业2021年第三季度报告

江中药业2021年第三季度报告

数据说|疫情下企业开启线上复工潮，远程办公或迎发展良机！

2020年 vol.05

艾媒咨询 | 2026年中国凉茶饮料消费趋势洞察白皮书

当前中国凉茶饮料行业正处于从传统快消品向健康饮品生态转型的关键窗口期，作为承载中医“治未病”理念与岭南饮食智慧的国家级非物质文化遗产，这一品类已成功从区域性民间饮品升级为全国性普及的健康消费品，尽管相较于行业增长高峰期，当前整体增速已有所放缓，但在宏观经济波动加剧及新兴饮品品类激烈竞争的双重压力下，凉茶行业依然展现出较强的市场韧性与抗风险能力。
根据全球新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2026年中国凉茶饮料消费趋势洞察白皮书》数据显示，2025年中国凉茶饮料市场规模达255.0亿元，行业已从跑马圈地的爆发期进入精耕细作的存量博弈期。83.4%的凉茶饮料消费是以自饮为核心，其中76.3%为强功能驱动。消费者购买凉茶饮料产品的首要决策因素为“清热降火”（54.2%），其次为“口感偏好”（46.3%）；重点关注产品的功效宣称及认证（46.1%）、口感试饮体验（45.0%）和配料表成分（43.6%），整体呈现“功效优先、体验为核、成分敏感”的特点。同时，消费者对不同包装有着非常理性的场景认知，根据不同需求精准选择适配的包装形态。
艾媒咨询分析师认为，存量博弈背景下，凉茶行业的竞争逻辑已从规模扩张转向价值提升，消费者的需求特征将成为驱动行业产品创新、渠道优化与品牌升级的核心导向。在产品层面，“清热降火”的传统核心需求仍将长期存在，但消费者需求正从单一功能向多元化延伸，低糖、无糖产品及添加益生元等功能性成分的创新产品，将成为破解行业增长瓶颈的关键。未来，只有精准把握消费者需求变化，持续推进产品创新、渠道升级与品牌赋能，将传统凉茶文化与现代健康消费理念深度融合，才能推动凉茶行业突破存量瓶颈，实现可持续增长，进一步巩固其在植物饮料领域的核心地位。
China's herbal tea beverage industry is currently in a critical window period of transitioning from traditional fast-moving consumer goods to a health beverage ecosystem. As a national intangible cultural heritage that embodies the traditional Chinese medicine concept of "preventive treatment" and Lingnan dietary wisdom, this category has successfully upgraded from a regional folk drink to a nationally popular health consumer product. Although the overall growth rate has slowed compared to the industry's peak growth period, the herbal tea industry continues to demonstrate strong market resilience and risk resistance despite the dual pressures of intensified macroeconomic fluctuations and fierce competition from emerging beverage categories.
According to the latest "White paper on China herbal tea beverages consumption trend insights in 2026" released by iiMedia Research, a global new economy industry third-party data mining and analysis institution, China's herbal tea beverage market reached 25.50 billion yuan in 2025, and the industry has entered a refined stock competition phase from the explosive expansion period. 83.4% of herbal tea beverage consumption is centered on personal consumption, of which 76.3% is driven by strong functional needs. The primary decision-making factor for consumers purchasing herbal tea beverage products is "heat-clearing and fire-purging" (54.2%), followed by "taste preference" (46.3%); consumers focus on product efficacy claims and certifications (46.1%), taste trial experience (45.0%), and ingredient list components (43.6%), presenting overall characteristics of "efficacy priority, experience as core, and ingredient sensitivity." Meanwhile, consumers have very rational scenario perceptions of different packaging formats, precisely selecting suitable packaging forms based on different needs.
iiMedia Research analysts believe that under the background of stock competition, the competitive logic of the herbal tea industry has shifted from scale expansion to value enhancement, and consumer demand characteristics will become the core driver for industry product innovation, channel optimization, and brand upgrading. At the product level, the traditional core demand for "heat-clearing and fire-purging" will continue to exist in the long term, but consumer demand is extending from single functions to diversification. Innovative products such as low-sugar, sugar-free products, and those with added functional ingredients like prebiotics will become the key to breaking through industry growth bottlenecks. In the future, only by precisely grasping changes in consumer demand, continuously advancing product innovation, channel upgrading, and brand empowerment, and deeply integrating traditional herbal tea culture with modern health consumption concepts, can the herbal tea industry break through stock bottlenecks, achieve sustainable growth, and further consolidate its core position in the plant beverage field.

中珠医疗控股股份有限公司2021年第三季度报告